Evidence map›Paper›PMID 29375887›Full record

ArticleJournal of pharmaceutical health care and sciences2018

A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.

Tetsuya Sasaki, Yasuhisa Kato, Atsushi Sato, Noriko Usui, Eishi Baba, Toshimi Takano, Nobuyuki Susumu, Kazunori Ohnishi, Hitomi Nishimoto, Katsuyuki Kiura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical health care and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tetsuya Sasaki1Department of Clinical Trial Support Center, Showa University Hospital, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555 Japan.
Yasuhisa Kato2Department of Drug Information, Showa University School of Pharmaceutical Sciences, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555 Japan.
Atsushi Sato3Department of Medical Oncology, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, 036-8562 Japan.
Noriko Usui4Department of Transfusion Medicine / Clinical Oncology and Hematology, The Jikei University Daisan Hospital, 4-11-1, Izumi-Honcho Komae-shi, Tokyo, 201-8601 Japan.
Eishi Baba5Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.
Toshimi Takano6Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470 Japan.
Nobuyuki Susumu7Department of Obstetrics and Gynecology, International University of Health and Welfare, 4-3 Kozunomori, Narita-shi, Chiba, 286-8686 Japan.
Kazunori Ohnishi8Japanese Red Cross Aichi Blood Center, 539-3 Minami-yamaguchi, Seto, Aichi 489-8555 Japan.
Hitomi Nishimoto9Department of Nursing, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama, 700-8558 Japan.
Katsuyuki Kiura10Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama, 700-8558 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical practice guidelines should be user-friendly and confirming their penetration rate and compliance are critical.

methodsWe conducted a nationwide web-based questionnaire survey among pharmacists regarding the 2013 guidelines for the appropriate use of granulocyte-colony stimulating factors (G

resultsA total of 301 pharmacists responded; 96.0% belonged to hospitals and were board-certified pharmacists in oncology pharmacy (

conclusionsTheir responses indicated that the respondents used the G-CSF guidelines and viewed them positively; however, the observation that about half of the respondents reported feeling that the guidelines do not match their current practice requires additional follow-up in future studies. The use of these guidelines should be routinely assessed in order to introduce novel cancer chemotherapy regimens and long-acting G-CSF in clinical practice.

Indexed as

Febrile neutropeniaGranulocyte Colony-stimulating factorNeoplasmsPharmacistPractice guidelines

Identifiers

PMID29375887
PMCPMC5772721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.